CA Patent

CA3035377A1 — Nanoparticle compositions for targeting t-cell cancers

Assigned to Mayo Clinic in Florida · Expires 2018-03-08 · 8y expired

What this patent protects

Described herein are compositions of binding agents and carrier proteins, and at least one therapeutic agent, wherein the binding agents are capable of binding an antigen expressed on T-cells and methods of making and using the same, in particular, as a T-cell cancer therapeutic.…

USPTO Abstract

Described herein are compositions of binding agents and carrier proteins, and at least one therapeutic agent, wherein the binding agents are capable of binding an antigen expressed on T-cells and methods of making and using the same, in particular, as a T-cell cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and at least one therapeutic agent, and methods of making and using the same, in particular, as a T-cell cancer therapeutic.

Drugs covered by this patent

Patent Metadata

Patent number
CA3035377A1
Jurisdiction
CA
Classification
—
Expires
2018-03-08
Drug substance claim
No
Drug product claim
No
Assignee
Mayo Clinic in Florida
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.